Factor VIII

Coagulation factor VIII; FVIII

Factor VIII (FVIII) is an essential blood coagulation protein, is a key component of the fluid phase blood coagulation system. Factor VIII is also a large procoagulant glycoprotein and a metal ion-dependent heterodimer that circulates in plasma in a noncovalent complex with von Willebrand factor. Factor VIII absence causes a severe bleeding disorder.

References:

[1]. Mazurkiewicz-Pisarek A, et al. The factor VIII protein and its function. Acta Biochim Pol. 2016;63(1):11-16. [Content Brief]

[2]. Fay PJ, Jenkins PV. Mutating factor VIII: lessons from structure to function. Blood Rev. 2005 Jan;19(1):15-27. [Content Brief]

[3]. Hoyer LW. Molecular pathology and immunology of factor VIII (hemophilia A and factor VIII inhibitors). Hum Pathol. 1987 Feb;18(2):153-61. [Content Brief]

Factor VIII Related Products (5):

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-P9940

Emicizumab
Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research.

HY-P99769

Omfiloctocog alfa
Omfiloctocog alfa (SCT-800) is a recombinant factor VIII (FVIII). FVIII is an essential blood coagulation protein and a key component of the fluid phase blood coagulation system. Omfiloctocog alfa can be used for the research of Hemophilia A.

HY-112998

Efmoroctocog alfa
Efmoroctocog alfa is a recombinant human coagulation factor VIII-Fc fusion protein (rFVIIIFc) that can be used for the research of haemophilia A.

HY-112865

Octocog alfa
Octocog alfa is a second-generation full-length recombinant factor VIII, as a antihemophilic factor.

HY-114128

Turoctocog alfa
Turoctocog alfa is a recombinant coagulation factor VIII (FVIII) from chinese hamster ovary (CHO) cells. Turoctocog alfa can be used for researching haemophilia A.

Name
Email *

	Sorry, but the email address you supplied was invalid.